Charles Riverの空売り状況は、投資家がCharles Riverの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Charles River (NYSE:CRL) 株価情報, 空売り情報

Charles River

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Charles River Laboratories International, Inc. Common Stock

Charles River Laboratories International Inc

Cresco Labs Inc

CARDINAL ENERGY LTD ORD by Cardinal Energy Ltd.

Cardinal Energy Ltd

CIRCUIT RESEARCH LABS INC by Circuit Research Labs, Inc.

Circuit Research Labs Inc

CENTRAL PRKNG F/T 5.25PFD by Central Parking Finance Trust

Central Parking Financial Trust

Cerillion PLC

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $175 to $165.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $165

Baird analyst Eric Coldwell maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $177 to $173.

Baird Maintains Neutral on Charles River, Lowers Price Target to $173

Barclays analyst Luke Sergott maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and lowers the price target from $166 to $160.

Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $160

On Wednesday, Charles River Laboratories International Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $983.63 million</a>.
In the fourth quarter of 2024, the operating margin decreased to (16.7)% from 13.1% a year ago, including a non-cash goodwill impairment of&nbsp;$215.0 million&nbsp;in the fourth quarter of 2024 related to the Biologics Solutions reporting unit, which includes the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808708/charles-river-laboratories-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-g" rel="noreferrer noopener">Biologics Testing and CDMO businesses</a>.
Adjusted operating margin increased to 19.9% from 19.1%, due primarily to higher revenue and operating income in the Manufacturing segment and lower unallocated corporate costs.
The company reported adjusted EPS of $2.66, down from $2.46 a year ago, surpassing the consensus estimate of $2.53.
James C. Foster, Chair, President and Chief Executive Officer, said, "Throughout 2024, we have launched initiatives to generate more revenue, aggressively reduce costs, and further strengthen our business. As we move into 2025, we see many of our global biopharmaceutical clients continuing to move forward with their restructuring and pipeline reprioritization activities, which are expected to constrain early-stage spending by many of these clients again in 2025.&#8221;
&#8220;We believe these trends are stabilizing, and therefore, our view of the global biopharmaceutical demand environment remains unchanged. In addition, small and mid-sized biotechnology clients continued to benefit from a more favorable funding environment in 2024, and we expect biotechnology demand trends will be stable to slightly improved this year."
Revenue for the Discovery and Safety Assessment segment was $603.3 million, down 3.6%. Organic revenue decreased by 3.5%, driven primarily by lower sales volume, as well as slightly lower pricing.
Research Models and Services&nbsp;sales increased 4.3% to $204.3 million.
The Noveprim acquisition in&nbsp;November 2023 contributed 4.8% to fourth-quarter RMS reported revenue, and the impact of foreign currency translation reduced revenue by 0.1%. Organic revenue decreased by 0.4%, due primarily to lower revenue for research models services and the Cell Solutions business, as well as lower sales for non-human primates in&nbsp;China.
Guidance:&nbsp;Charles River Laboratories expects 2025 revenue to decline between 7% and 4.5% on a reported basis and 5.5% and 3.5% organically.
Charles River sees the fiscal year 2025 adjusted EPS of $9.10-$9.60 versus a consensus of $9.60.
William Blair analyst Max Smock writes that the initial release reinforced the view that Charles River remains the premier preclinical CRO, and the analyst is confident in its best-in-class offerings.
&#8220;There is too much working against the company in the near term to make the stock interesting,&#8221; analyst writes. William Blair <a target="_blank" href="https://www.benzinga.com/quote/CRL/analyst-ratings" rel="noreferrer noopener">reiterates the Market Perform rating</a>.
Price Action: At last check on Wednesday, CRL stock closed up 6.87% to $165.01.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43816882/manchester-uniteds-q2-revenue-drops-12-but-ebitda-forecasts-brighten-fiscal-2025" target="_blank" rel="noreferrer noopener">Manchester United&#8217;s Q2 Revenue Drops 12%, But EBITDA Forecasts Brighten Fiscal 2025</a></li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Charles River Sees FY25 Adjusted EPS Of $9.10-$9.60 Vs. $9.60 Estimate

Charles River Plans To Repurchase Approximately $350M In Common Stock In 2025

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.53 by 5.14 percent. This is a 8.13 percent increase over earnings of $2.46 per share from the same period last year. The company reported quarterly sales of $1.003 billion which beat the analyst consensus estimate of $983.627 million by 1.97 percent. This is a 1.03 percent decrease over sales of $1.013 billion the same period last year.

Earnings Beats

Charles River Q4 2024 Adj. EPS $2.66 Beats $2.53 Estimate, Sales $1.003B Beat $983.627M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Throughout the last three months, 6 analysts have evaluated Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Charles River, revealing an average target of $185.0, a high estimate of $210.00, and a low estimate of $166.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.54%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739901640_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Charles River's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$184.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Charles River's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>Discovering Charles River: A Closer Look</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>A Deep Dive into Charles River's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Charles River's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -1.64%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Charles River's ROA excels beyond industry benchmarks, reaching 0.86%. This signifies efficient management of assets and strong financial health.
Debt Management: Charles River's debt-to-equity ratio is below the industry average. With a ratio of 0.73, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Charles River's Future

Barclays analyst Luke Sergott maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and lowers the price target from $205 to $166.

Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $166

<ul>
<li>Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. &nbsp;</li>
<li>The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). &nbsp;</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 13, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PUORgMWD9s54SxWedlx-lzOf1r6NgAht299y5lTn9a6Vsqfr7-YbDssYsMe4Jy5BrCx9GuY-dOlLT2wD9bnNAk44ovjeJE2zoAyUDankfwG6h_9R6UnXqD0TU2Cxzm6S">Conduit Pharmaceuticals Inc.</a>&nbsp;(Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=Wf4MnZPznzgV77ZlyUQd6O3jH76aPtoRrHW3e9rUTAAj50f3NAkhaxwCUUkuXqEBRZm8AhL32eBU2fpgQSo_VVQnVqLrD7OUu9-PCAusL6tNdYYRllD0bYc47BPsyxqR4zM8B3LDMqXE4Tj5IlGJkRjJ5yt7XsrVaa5-vex7X7vXKKjikhxL9e1oA9I1GReuWasxAhP_46sFKLpVTSxfJfo_408pHHmwyk_t2NADGMz50Y_Xi1GEV4KCuTvk4Vwn">CDT)</a> ("Conduit" or the "Company"), is pleased to announce an agreement with Charles River Laboratories Inc ("Charles River") to evaluate AZD1656 (and its derivatives) in a clinically relevant Systemic Lupus Erythematosus model. This collaboration highlights Conduit's focus on generating high-quality preclinical data to optimize the development pathway for its clinical program in auto-immune and position itself for success in its upcoming Phase II clinical trials.
Conduit will leverage Charles River's expertise in immunology and preclinical research to refine study parameters and generate robust data to evaluate the efficacy of its lead compound. By conducting this comprehensive study, Conduit aims to enhance the predictability of clinical outcomes, increase the efficiency of its planned Phase II trials, and ultimately improve the likelihood of success for AZD1656 as a potential treatment for autoimmune disorders.
This study is a critical step in Conduit's development strategy, as it is expected to provide essential data to inform and de-risk future clinical trials. The primary aim is to better understand the impact of drug on disease progression in a lupus model, assessed by typical disease progression readouts. Furthermore, the study will gather data on the effect of the drug on inflammatory markers and pro-inflammatory cytokine levels to understand how the drug impacts Treg immunoregulation.
By generating this data early in the development process, Conduit aims to optimize its Phase II trials, by reducing development timelines and maximizing the therapeutic potential of AZD1656. This will strengthen the scientific foundation for Conduit's primary asset but also enhance the value for potential out-licensing opportunities.

Biotech

Conduit Pharmaceuticals Partners With Charles River To Evaluate AZD1656 In Pre-Clinical Lupus Model; Aims To Enhance Phase II Trial Outcomes For Autoimmune Disorders, Focus On Lupus

Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and lowers the price target from $220 to $184.

Morgan Stanley Maintains Equal-Weight on Charles River, Lowers Price Target to $184

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $215 to $175.

JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $175

6 analysts have shared their evaluations of Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop is evident in the current average compared to the previous average price target of $220.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658851_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Charles River among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$227.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$225.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Charles River's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Charles River faced challenges, resulting in a decline of approximately -1.64% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Charles River's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Charles River Stock

Goldman Sachs analyst Matthew Sykes maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Buy and lowers the price target from $220 to $190.

Goldman Sachs Maintains Buy on Charles River, Lowers Price Target to $190

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Eddy Wang downgraded the rating for New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Overweight Equal-Weight and lowered the price target from $83 to $52. New Oriental Education shares closed at $46.71 on Tuesday. <a href="https://www.benzinga.com/quote/EDU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Simon Coles downgraded STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Equal-Weight to Underweight. STMicroelectronics shares closed at $25.75 on Tuesday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Mark Murphy downgraded Paycor HCM, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Neutral to Underweight but raised the price target from $21 to $22.5. Paycor HCM shares closed at $22.12 on Tuesday. <a href="https://www.benzinga.com/quote/PYCR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Max Smock downgraded Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to Market Perform. Charles River shares closed at $169.81 on Tuesday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith downgraded the rating for Fluence Energy, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Buy to Hold and slashed the price target from $22 to $15. Fluence Energy shares closed at $14.41 on Tuesday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying STM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22065724/image-148-1024x611.png" alt="" class="wp-image-744546" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22065724/image-148-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22065724/image-148-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22065724/image-148-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22065724/image-148.png 1070w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

New Oriental Education & Technology Group

FLNC

PYCR

This STMicroelectronics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

William Blair analyst Max Smock downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to Market Perform.

William Blair Downgrades Charles River to Market Perform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Devin Brisco downgraded the rating for Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Outperform to Peer Perform. Spotify shares closed at $490.34 on Thursday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Andrew Didora downgraded JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) from Neutral to Underperform and maintained the price target of $6.5. JetBlue Airways shares closed at $7.61 on Thursday. <a href="https://www.benzinga.com/quote/JBLU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Adam Borg downgraded Rapid7 Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Buy to Hold and lowered the price target from $48 to $42. Rapid7 shares closed at $39.79 on Thursday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Dan Leonard downgraded the rating for Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Buy to Neutral and lowered the price target from $250 to $185. Charles River shares closed at $165.80 on Thursday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss downgraded the rating for Lucky Strike Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUCK#NYSE">LUCK</a>) from Overweight to Neutral and lowered the price target from $15 to $12. Lucky Strike shares closed at $10.59 on Thursday. <a href="https://www.benzinga.com/quote/LUCK/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17085627/image-123-1024x612.png" alt="" class="wp-image-739047" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17085627/image-123-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17085627/image-123-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17085627/image-123-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17085627/image-123.png 1083w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

JBLU

LUCK

SPOT

This Spotify Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

UBS analyst Dan Leonard downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Buy to Neutral and lowers the price target from $250 to $185.

UBS Downgrades Charles River to Neutral, Lowers Price Target to $185

Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) and Akron Bio ("Akron"), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron's Closed System Solutions (CSS)&#x2122; line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River's Cell Therapy Flex Platform for Process Development. The integration of Akron's line of liquid cytokines further enables closed system processing, which streamlines operations, minimizes risk, and improves process robustness.
Charles River's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F4f2gkJY&amp;esheet=54180356&amp;newsitemid=20250116351889&amp;lan=en-US&amp;anchor=Cell+Therapy+Flex+Platform&amp;index=1&amp;md5=7cd61c2cf17b665d78291e747e7c38c3">Cell Therapy Flex Platform</a> was designed as an off-the-shelf solution for Cell Therapy Process Development, offering ready-to-use platforms and protocols validated for autologous CAR-T and TCR-T cells therapies to minimize risk, reduce cost, and speed development timelines. Automated platforms with closed systems have protocols ranging from cell selection and expansion to electroporation and wash/concentration to fill and finish.

Charles River And Akron Bio Announces Integration Of Akron's Closed System Solutions Line Onto Charles River's Cell Therapy Flex Platform To Enhance Cell Therapy Process Development

Press Releases

Charles River Laboratories to Present at UBS and Jefferies Conferences

Charles River Laboratories to Present at Evercore ISI Investor Conference

Charles River Introduces Global Biotech Incubator Program

Deciphex Secures $32.3M Series C to Address Global Pathology Shortage

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Charles River

空売り

Charles River (NYSE:CRL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル